Free Trial
→ Elon Takes Aim at Social Security (From Altimetry) (Ad)

Unity Biotechnology 11/4/2024 Earnings Report

Unity Biotechnology logo
$1.94 -0.11 (-5.37%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Unity Biotechnology EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Unity Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Unity Biotechnology Announcement Details

Quarter
Date
11/4/2024
Time
After Market Closes

Conference Call Resources

Unity Biotechnology Earnings Headlines

Unity Biotechnology CFO sells shares worth $341
February 5, 2025 | msn.com
Unity Biotechnology CEO Anirvan Ghosh sells shares worth $1,431
February 5, 2025 | msn.com
$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
February 22, 2025 | Altimetry (Ad)
UBX stock touches 52-week high at $2.02 amid market optimism
January 22, 2025 | msn.com
Chardan Capital Initiates Coverage of Unity Biotechnology (UBX) with Buy Recommendation
January 11, 2025 | msn.com
UNITY Biotechnology Reports Granting of New Employment Inducement Award
January 7, 2025 | globenewswire.com
See More Unity Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Unity Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unity Biotechnology and other key companies, straight to your email.

About Unity Biotechnology

Unity Biotechnology (NASDAQ:UBX), a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

View Unity Biotechnology Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles